Adjunctive therapy with an oral H 2 S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction.
Jake E DoironHuijing XiaXiaoman YuAlexandra R NevinsKyle B LaPennaThomas E SharpTraci T GoodchildTimothy D AllertonMona ElgazzazEric D LazartiguesSanjiv J ShahZhen LiDavid J LeferPublished in: British journal of pharmacology (2024)
S therapy while also revealing the superior efficacy of the combination therapy in cardiometabolic HFpEF.